Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light

Fryk, Jesse J., Marks, Denese C., Hobson-Peters, Jody, Prow, Natalie A., Watterson, Daniel, Hall, Roy A., Young, Paul R., Reichenberg, Stefan, Sumian, Chryslain and Faddy, Helen M. (2016) Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light. Transfusion, . doi:10.1111/trf.13729


Author Fryk, Jesse J.
Marks, Denese C.
Hobson-Peters, Jody
Prow, Natalie A.
Watterson, Daniel
Hall, Roy A.
Young, Paul R.
Reichenberg, Stefan
Sumian, Chryslain
Faddy, Helen M.
Title Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light
Journal name Transfusion   Check publisher's open access policy
ISSN 1537-2995
0041-1132
Publication date 2016
Year available 2016
Sub-type Article (original research)
DOI 10.1111/trf.13729
Open Access Status Not Open Access
Total pages 8
Place of publication Hoboken, NJ United States
Publisher Wiley-Blackwell
Collection year 2017
Language eng
Formatted abstract
BACKGROUND: Arboviruses, such as dengue viruses(DENV) and chikungunya virus (CHIKV), pose a risk tothe safe transfusion of blood components, includingplasma. Pathogen inactivation is an approach to managethis transfusion transmission risk, with a number oftechniques being used worldwide for the treatment ofplasma. In this study, the efficacy of the THERAFLEXMB-Plasma system to inactivate all DENV serotypes(DENV-1, DENV-2, DENV-3, DENV-4) or CHIKV inplasma, using methylene blue and light illumination at630 nm, was investigated.

STUDY DESIGN AND METHODS
: Pooled plasmaunits were spik ed with DENV-1, DENV-2, DENV-3 DENV-4,or CHIKV and treated with the THERAFLEX MB-Plasmasystem at f our light illumination doses: 20, 40, 60, and 120(standard dose) J/cm2. Pr e- and posttreatment sampleswere collected and viral inf ectivity was determined. Thereduction in viral infe ct ivity was calculated f or each dose.

RESULTS: Treatment of plasma with the THERAFLEXMB-Plasma system resulted in at least a 4.46-logreduction in all DENV serotypes and CHIKV infectiousvirus. The residual infectivity for each was at thedetection limit of the assay used at 60 J/cm2, with dosedependency also observed.

CONCLUSIONS
: Our study demonstrated theTHERAFLEX MB-Plasma system can reduce theinfectivity of all DENV serotypes and CHIKV spiked intoplasma to the detection limit of the assay used at half ofthe standard illumination dose. This suggests this systemhas the capacity to be an effective option for managingthe risk of DENV or CHIKV transfusion transmission inplasma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: HERDC Pre-Audit
Admin Only - School of Medicine
School of Chemistry and Molecular Biosciences
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Fri, 29 Jul 2016, 10:05:24 EST by Mrs Louise Nimwegen on behalf of School of Chemistry & Molecular Biosciences